PFE · 8-K · 20260804PR000094

Product / Drug Pipeline Progress

PFIZER INC · 2026-08-04 · Importance 31 · Surprise 42 · In source text

Pfizer reported positive Phase 2b results for berobenatide, an investigational monthly GLP-1 receptor agonist peptide, showing competitive weight loss, favorable tolerability and low gastrointestinal adverse events in participants with obesity or overweight. The company plans to advance 10 Phase 3 berobenatide studies in 2026 for chronic weight management and obesity-related comorbidities, within a broader program of more than 20 obesity trials. A 25-valent pneumococcal conjugate vaccine candidate demonstrated robust immunogenicity and expanded protection across 25 serotypes in infants, supporting the start of a pivotal Phase 3 pediatric program. By contrast, the Phase 3 SigVie-002 study of sigvotatug vedotin did not show a statistically significant overall-survival improvement versus docetaxel in previously treated non-squamous non-small cell lung cancer.

Key facts

• Talzenna plus Xtandi in TALAPRO-3 demonstrated 52% reduction in risk of radiographic progression or death (HR 0.48; 95% CI 0.36–0.65; p < 0.0001); three-year rPFS rates 77% vs 56% source
• Phase 3 BREAKWATER cohort 3 Braftovi combination PFS result: 56% reduction in risk of progression or death (HR 0.44; 95% CI 0.27–0.70; p=0.0002); updated OS showed 44% reduction (HR 0.56; 95% CI 0.34–0.94) with median follow-up ~20 months source
• FDA approved expanded indication for Hympavzi in June 2026 to include treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients ages 6 to 11 with or without inhibitors; Hympavzi now indicated in U.S. for routine prophylaxis in adults and pediatric patients 6 years and older source
• FDA approved Ibrance in June 2026 in combination with trastuzumab (with or without pertuzumab) and endocrine therapy for maintenance treatment of HR+/HER2+ locally advanced or metastatic breast cancer following induction treatment source
• Pfizer intends to submit global regulatory filings for Litfulo based on positive Phase 3 TRANQUILLO results (July 2026) source
• July 2026 FDA approved Padcev plus pembrolizumab (and combinations) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer regardless of cisplatin eligibility source
• FDA accepted Talzenna sNDA for priority review in July 2026 with a PDUFA action date in the last quarter of 2026 source
• Berobenatide Phase 2b results (June 2026) support plan to advance 10 Phase 3 studies in 2026 as part of broader program of 20+ obesity trials source

Impact estimates